AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

IRB/UVA Tracking #
19229
Contact
Candace K Hudspeth
Contact Email
Contact Phone
1.434.982.1091
Phase
III
Primary purpose
Treatment
Cancer PI
William C. Petersen
Status
OPEN TO ACCRUAL